XNAS · Healthcare · Biotechnology
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Q4 2025 | — | -626.00 | — | $0 | — | +1.98% | -32.98% | -63.06% |
| 2025-08-14 | Q2 2025 | — | -5.46 | — | $0 | — | -1.80% | -7.78% | -64.07% |
| 2025-03-28 | Q4 2024 |
| — |
| -1.53 |
| — |
| $0 |
| — |
| -12.25% |
| -27.45% |
| -38.76% |
| 2024-11-14 | Q3 2024 | — | -7.00 | — | $0 | — | -9.05% | +14.91% | -21.30% |
| 2024-08-12 | Q2 2024 | — | -7.00 | — | $0 | — | -19.12% | -6.94% | -16.18% |
| 2024-05-14 | Q1 2024 | — | -5.00 | — | $0 | — | +4.58% | +5.63% | -28.87% |
| 2024-02-16 | Q4 2023 | — | -2.00 | — | $0 | — | — | — | — |
| 2023-11-20 | Q3 2023 | — | 0.00 | — | $0 | — | +1.56% | +78.13% | +294.53% |
Showing last 8 quarters.